Your Specialist CRO For Nasal & Inhaled Drug Products
Nanopharm is focused on providing highly specialized OINDP development and analytical services that accelerate the development of your drug-device combination product and help bring it to market faster.
Nanopharm applies its specialized expertise across a range of OINDP drug delivery formats and molecule types. Our specialty is developing nasal and inhaled drug delivery products for small molecules or biologics in combination with a variety of devices suitable for innovator, generic, or lifecycle management applications.
Nanopharm's OINDP Development Services
Our scientists are dedicated to advancing customer OINDP products from early development to cGMP clinical stages and providing ongoing analytical support through to commercialization and beyond. With over 20 years of experience developing some of the world’s most advanced nasal, inhaled, and inhaled biologic products, Nanopharm offers the right support and services for virtually every stage of your drug product’s development. All our services are backed by world-class regulatory support and unrivaled scientific expertise.
As part of Aptar Pharma’s strategic expansion to support early-stage drug development, Nanopharm now integrates the clinical trial manufacturing capabilities available at our newly acquired Aptar Boonton sister site a recognized leader in Phase 1 and 2 fill and finish services for Orally Inhaled and Nasal Drug Products (OINDPs). This acquisition strengthens our ability to offer end-to-end support from early development through clinical supply. Aptar Boonton combines decades of CMC experience with a laser focus on OINDPs to transform your project into a clinic-ready proposition.
Using a stage-appropriate methodology within the Module 3 framework, our experts work collaboratively with you to manage risk, mitigate delay and reduce cost while ensuring your OINDP product’s quality, safety, and efficacy.
Nanopharm’s OINDP Expertise
Nanopharm applies its specialized expertise across a range of OINDP drug delivery formats and molecule types. Our specialty is developing nasal and inhaled drug delivery products for small molecules or biologics for a variety of drug delivery technologies suitable for innovator, generic or lifecycle management applications. Our scientists are dedicated to advancing customer OINDP products from early development to cGMP clinical stages, and ongoing analytical support through to commercialization and beyond.
Nanopharm SmartTrack ™
Nanopharm has developed a unique proprietary in-vitro in-silico modeling system that can demonstrate the comparative bioequivalence (BE) of inhaled generic drug products to reference listed products without conducting a comparative clinical endpoint (CCEP) study.
Nanopharm & Low GWP Propellant Inhalers
As the world moves forward with a growing focus on sustainability and protecting the environment, Nanopharm is committed to helping OINDP customers meet their sustainability objectives. Nanopharm is researching how to reformulate pressurized metered dose inhalers (pMDIs) that use lower Global Warming Potential (GWP) propellants. As a result, Nanopharm is helping customers advance a more sustainable next-generation of inhaled drug products while retaining the safety and efficacy of existing marketed products.
Contact Nanopharm
Contact Nanopharm today to accelerate development of your nasal or inhalation product with our specialized technical knowledge, regulatory support, and unique development capabilities.
